Current clinical trials for the treatment of Alzheimer's disease (as of... | Download Table
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval | Semantic Scholar
Frontiers | Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease | Neuroscience
Frontiers | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease | Frontiers in Computational Neuroscience
Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions - IOS Press
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment | Expert Reviews in Molecular Medicine | Cambridge Core
Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401) - touchNEUROLOGY
P4‐704: BAN2401 SHOWS STRONGER BINDING TO SOLUBLE AGGREGATED AMYLOID‐BETA SPECIES THAN ADUCANUMAB - Lannfelt - 2019 - Alzheimer's & Dementia - Wiley Online Library
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease | Nature Reviews Neurology
S-1
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
Biogen: BAN2401 Not A Home Run Anymore, But Still Holds Some Promise — The Non-Consensus
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
Novel Treatments for Alzheimer Disease Disorders - Practical Neurology
Monoclonal antibodies against β-amyloid currently in phase III clinical... | Download Scientific Diagram
S-1/A
Advisory Council January 2018 Meeting Presentation: Overview on NIA Preclinical Pipeline | ASPE
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review - ScienceDirect
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
BioArctic's new collaboration with Eisai on BAN2401
xmlinkhub
Alzheimer's disease drug development pipeline: 2017 - Cummings - 2017 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE | News Release：2010 | Eisai Co., Ltd.
